Achieve Life Sciences Inc (ACHV) Stock Price, Quote & News

Company Profile

Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms. It has license and supply agreements with Sopharma AD and University of Bristol. Achieve Life Sciences, Inc., is headquartered in Bothel...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 210 2217

Website: www.achievelifesciences.com

Address:

22722 29th Dr. SE, Suite 100, Bothell, United States

BG_BULL Jun. 24 at 1:59 PM

$ACHV Let the countdown to Russell Index entry begin now! And passive funds need millions of shares 😎

0 · Reply

Gdellinger Jun. 23 at 7:32 PM

$ACHV hc wainwright put a $12 target

2 · Reply

Sieppo Jun. 22 at 6:09 PM

$ACHV no position yet but IMO the biggest bullish thesis at the moment could be the confirmation, that the FDA didn't find any other problems than the manufacturing one (it was expected yes but not confirmed). I mean think what this means to a possible suitor or company thinking about acquiring them, looks like pretty derisked at a discount.

1 · Reply

bobtheknob Jun. 22 at 5:46 PM

$ACHV Fantastic update today. Achieve received a Clean CRL from the FDA! Everything the new management has communicated since April 15 has turned about to be true and we are on track for new NDA in Q4. Zero clinical issues, the root cause was the third party manufacture, and labeling. The path forward has been Adare, the tech transfer, and new NDA. The bottom is in and we have further been de-risked!

1 · Reply

inmarketswetrust Jun. 22 at 5:19 PM

$ACHV will be opportunities to add between now and resubmission/ being patient to get a sub $5 entry

2 · Reply

MrTicker Jun. 22 at 4:38 PM

$ACHV Achieve plans to resubmit the NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner. If approved, the company expects potential FDA approval in the first half of 2027, followed by a U.S. commercial launch.

0 · Reply

MrTicker Jun. 22 at 4:37 PM

$ACHV FDA Declines To Approve Achieve Life Sciences' Smoking Cessation Drug; Q4 Resubmission Planned BENZINGA 10:44 AM ET 6/22/2026 Achieve Life Sciences Inc. (ACHV) on Monday received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application seeking approval of cytisinicline, its investigational treatment for nicotine dependence. The company said the FDA’s concerns were tied to manufacturing-related issues at a former third-party facility and incomplete final product labeling, while no deficiencies were identified regarding the drug’s safety or efficacy. In March, the company reported that the FDA inspected one manufacturer named in the cytisinicline application and identified two observations related to solid oral dose manufacturing.

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:37 PM

$ACHV Lol. All sellers continuing to take losses.

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:34 PM

$ACHV Lol. Panic sellers taking substantial losses.

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:31 PM

$ACHV Lol. All sales are at a loss.

0 · Reply

Achieve Life Sciences CRL from FDA cites deficiencies at manufacturing facility

Jun 22, 2026, 8:54 AM EDT - 2 days ago

US FDA declines to approve Achieve Life Sciences' smoking-cessation drug

Jun 22, 2026, 8:30 AM EDT - 2 days ago

Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA

Jun 8, 2026, 8:00 AM EDT - 16 days ago

Achieve Life Sciences Proxy statement: Proxy filing

Jun 2, 2026, 8:30 AM EDT - 22 days ago

Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors

May 29, 2026, 8:00 AM EDT - 26 days ago

Achieve Life Sciences Proxy statement: Proxy filing

May 19, 2026, 2:15 PM EDT - 5 weeks ago

Achieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline Treatment

2026-05-12T21:31:08.000Z - 6 weeks ago

Achieve Life Sciences files prospectus for resale of shares by holders

May 12, 2026, 8:30 AM EDT - 6 weeks ago

Achieve Life Sciences Earnings Call Transcript: Q1 2026

May 12, 2026, 8:30 AM EDT - 6 weeks ago

Achieve Life Sciences Earnings release: Q1 2026

May 12, 2026, 8:30 AM EDT - 6 weeks ago

Achieve Life Sciences Quarterly report: Q1 2026

May 12, 2026, 8:00 AM EDT - 6 weeks ago

Achieve Life Sciences Registration statement: Registration filing

2026-05-12T11:58:27.000Z - 6 weeks ago

Achieve Life Sciences reports Q1 EPS (19c), consensus (30c)

May 12, 2026, 7:05 AM EDT - 6 weeks ago

Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma

May 12, 2026, 7:00 AM EDT - 6 weeks ago

Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Updates

May 5, 2026, 8:30 AM EDT - 7 weeks ago

Achieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026

May 1, 2026, 7:00 AM EDT - 7 weeks ago

Achieve Life Sciences Slides: Corporate presentation

2026-04-21T09:20:14.000Z - 2 months ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-20T20:46:40.000Z - 2 months ago

Achieve Life Sciences initiated with a Buy at Canaccord

2026-04-16T15:25:18.000Z - 2 months ago

Achieve Life Sciences announces $354M private placement

2026-04-16T14:03:48.000Z - 2 months ago

Achieve Life Sciences appoints Goldberg as CEO, names two leaders to board

Apr 16, 2026, 8:57 AM EDT - 2 months ago

Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors

Apr 16, 2026, 8:53 AM EDT - 2 months ago

Achieve Life Sciences Announces Up to $354 Million Private Placement

Apr 15, 2026, 8:00 AM EDT - 2 months ago

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Mar 26, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability

Mar 24, 2026, 2:23 PM EDT - 3 months ago

Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 24, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Annual report: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences Earnings release: Q4 2025

2026-03-24T11:10:44.000Z - 3 months ago

Achieve Life Sciences reports Q4 EPS (28c), consensus (28c)

Mar 24, 2026, 7:00 AM EDT - 3 months ago

Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 17, 2026, 8:30 AM EDT - 3 months ago

Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026

2026-03-09T20:45:55.000Z - 3 months ago

Aeon Biopharma appoints John Bencich as CFO

AEON

2026-03-04T13:21:27.000Z - 4 months ago

Achieve Life Sciences announces new data on cytisinicline to be presented

Mar 4, 2026, 8:00 AM EST - 4 months ago

Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study

2026-02-06T16:15:23.000Z - 4 months ago

H.C. Wainwright says Chantix news ‘significant win’ for Achieve Life Sciences

PFE

Jan 30, 2026, 4:05 PM EST - 5 months ago

Achieve Life Sciences Announced Granting of New Hire Inducement Awards

2026-01-23T21:10:26.000Z - 5 months ago

Achieve Life Sciences files $300M mixed securities shelf

Jan 23, 2026, 7:00 AM EST - 5 months ago

Achieve Life Sciences Registration statement: Registration Filing

2026-01-12T13:55:17.000Z - 5 months ago

Achieve Life Sciences confirms promotion of Mark Rubinstein to CMO

Jan 12, 2026, 8:47 AM EST - 5 months ago

Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer

Jan 12, 2026, 7:00 AM EST - 5 months ago

Achieve Life Sciences Slides: Corporate presentation

2026-01-05T16:45:30.000Z - 6 months ago

H.C. Wainwright names two best 2026 ideas in SMID-cap biopharma

CNTB

2025-12-30T16:10:10.000Z - 6 months ago

Achieve Life near FDA approval of smoking addiction treatment, Hunterbrook says

Dec 17, 2025, 4:11 PM EST - 6 months ago

Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week

2025-11-25T09:45:19.000Z - 7 months ago

Achieve Life Sciences initiated with an Outperform at Citizens JMP

Nov 6, 2025, 8:30 AM EST - 8 months ago

Achieve Life Sciences Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Achieve Life Sciences Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Achieve Life Sciences Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Nov 5, 2025, 7:00 AM EST - 8 months ago

Achieve Life Sciences Slides: Corporate Presentation

Nov 3, 2025, 8:30 AM EST - 8 months ago

Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation

Oct 29, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025

Oct 20, 2025, 8:30 AM EDT - 8 months ago

Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer

Oct 17, 2025, 7:30 AM EDT - 8 months ago

Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation

Oct 2, 2025, 4:01 PM EDT - 9 months ago

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

Sep 22, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD

Sep 18, 2025, 8:30 AM EDT - 9 months ago

Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer

Sep 11, 2025, 5:01 PM EDT - 10 months ago

Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer

Sep 8, 2025, 11:00 AM EDT - 10 months ago

Achieve Life Sciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Sep 2, 2025, 8:30 AM EDT - 10 months ago

Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences Quarterly report: Q2 2025

Aug 7, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences Earnings release: Q2 2025

Aug 7, 2025, 7:30 AM EDT - 11 months ago

Achieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program

Aug 6, 2025, 6:00 PM EDT - 11 months ago

Achieve Life Sciences Slides: Corporate Presentation

Jul 29, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences to Participate in the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 11 months ago

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Slides: Corporate Presentation

Jun 30, 2025, 7:52 PM EDT - 1 year ago

Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional Securities

Jun 26, 2025, 11:43 PM EDT - 1 year ago

Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering

Jun 26, 2025, 4:03 PM EDT - 1 year ago

Achieve Life Sciences Announces Proposed Underwritten Public Offering

Jun 26, 2025, 4:02 PM EDT - 1 year ago

Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

OMC

Jun 4, 2025, 5:30 PM EDT - 1 year ago

Achieve Life Sciences Transcript: Jefferies Global Healthcare Conference 2025

May 28, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Quarterly report: Q1 2025

May 13, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings release: Q1 2025

May 13, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

May 6, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Achieve Life Sciences Proxy statement: Proxy Filing

Apr 21, 2025, 11:19 AM EDT - 1 year ago

Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

Mar 12, 2025, 11:30 AM EDT - 1 year ago

Achieve Life Sciences Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Achieve Life Sciences Earnings release: Q4 2024

Mar 11, 2025, 7:30 AM EDT - 1 year ago

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

Mar 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference

Mar 6, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025

Feb 11, 2025, 10:00 AM EST - 1 year ago

Achieve Life Sciences Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference

Feb 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Jan 10, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

Jan 7, 2025, 8:30 AM EST - 1 year ago

Achieve Life Sciences Announces Critical Milestone Successfully Reached in ORCA-OL Cytisinicline Clinical Trial Required for NDA Submission

Dec 9, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

Dec 3, 2024, 8:30 AM EST - 1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

BG_BULL Jun. 24 at 1:59 PM

$ACHV Let the countdown to Russell Index entry begin now! And passive funds need millions of shares 😎

0 · Reply

Gdellinger Jun. 23 at 7:32 PM

$ACHV hc wainwright put a $12 target

2 · Reply

Sieppo Jun. 22 at 6:09 PM

1 · Reply

bobtheknob Jun. 22 at 5:46 PM

1 · Reply

inmarketswetrust Jun. 22 at 5:19 PM

$ACHV will be opportunities to add between now and resubmission/ being patient to get a sub $5 entry

2 · Reply

MrTicker Jun. 22 at 4:38 PM

0 · Reply

MrTicker Jun. 22 at 4:37 PM

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:37 PM

$ACHV Lol. All sellers continuing to take losses.

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:34 PM

$ACHV Lol. Panic sellers taking substantial losses.

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:31 PM

$ACHV Lol. All sales are at a loss.

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:29 PM

$ACHV Lol. All sales are at a loss.

0 · Reply

Trigga_tha_Gambler Jun. 22 at 4:26 PM

$ACHV Lol. Losses incoming for sellers.

0 · Reply

notreload_ai Jun. 22 at 3:23 PM

$ACHV received an FDA Complete Response Letter for its cytisinicline NDA due to manufacturing issues at a former facility. No efficacy or safety deficiencies were identified. https://notreload.xyz/xy/achieve-life-sciences-receives-fda-crl-for-cytisinicline/

0 · Reply

dwilkos Jun. 22 at 3:08 PM

$ACHV that $4.50 premarket fill is looking strong

0 · Reply

BG_BULL Jun. 22 at 2:58 PM

$ACHV Today we are tearing shorts! 😎 It was quite stupid to sell news that has long been known and included in the share price.

0 · Reply

gretaslaps Jun. 22 at 12:56 PM

$ACHV rejected

1 · Reply

NYPD Jun. 22 at 12:41 PM

$ACHV and again waiting for Q4 2026. So frustrating!

0 · Reply

Sieppo Jun. 22 at 12:37 PM

$ACHV It's a damn shame that they 99% would have gotten a straight approval today if they hadn't totally fucked up the manufactoring part..

1 · Reply

MrTicker Jun. 22 at 12:34 PM

$ACHV Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA GLOBENEWSWIRE 7:30 AM ET 6/22/2026 "Achieve has completed the analytical method technology transfer to Adare’s facility, successfully manufactured its first cytisinicline engineering batch, and fully qualified all testing procedures at the site. Achieve intends to resubmit its NDA in the fourth quarter of 2026, naming Adare as its primary manufacturing partner, with potential FDA approval in the first half of 2027, followed by U.S. commercial launch."

0 · Reply

TA_Kongen Jun. 22 at 12:34 PM

$ACHV Amateurs. The CRL cites manufacturing-related deficiencies at a prior third-party facility and incomplete product labeling

1 · Reply

ChristIsKingg Jun. 22 at 12:32 PM

$ACHV https://ir.achievelifesciences.com/news-events/press-releases/detail/264/achieve-life-sciences-receives-complete-response-letter-from-fda-for-cytisinicline-nda

0 · Reply

bobtheknob Jun. 22 at 11:16 AM

$ACHV Why is Achieve not releasing the news already? Expecting something premarket.

1 · Reply

Market Cap	523.56M
Revenue (ttm)	0.00
Net Income (ttm)	-54.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.53

Volume	2,083,700
Avg Vol	1,836,188
Day's Range	N/A - N/A
Shares Out	102.66M
Stochastic %K	36%
Beta	2.27
Analysts	Strong Sell
Price Target	$13.62